

# Richard L Wahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5892088/publications.pdf>

Version: 2024-02-01

310  
papers

23,815  
citations

9428

76  
h-index

9865

146  
g-index

326  
all docs

326  
docs citations

326  
times ranked

20136  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | A Projection-Domain Low-Count Quantitative SPECT Method for $^{67}\text{Ga}$ -Particle-Emitting Radiopharmaceutical Therapy. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2023, 7, 62-74.  | 2.7 | 4         |
| 2  | Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 550-562.  | 3.3 | 48        |
| 3  | Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development. <i>Journal of Nuclear Medicine</i> , 2022, 63, 500-510.   | 2.8 | 43        |
| 4  | Brown Adipose Tissue: A Protective Mechanism Against "Preprediabetes". <i>Journal of Nuclear Medicine</i> , 2022, 63, 1433-1440.  | 2.8 | 4         |
| 5  | Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2300-2309.  | 3.3 | 20        |
| 6  | Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1836-1843.  | 2.8 | 5         |
| 7  | A Snapshot of Radiology Training During the Early COVID-19 Pandemic. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 607-613.   | 0.6 | 18        |
| 8  | Overview of the First NRG Oncology "National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1133-1139.  | 2.8 | 5         |
| 9  | Repeatability of Radiomic Features of Brown Adipose Tissue. <i>Journal of Nuclear Medicine</i> , 2021, 62, 700-706.   | 2.8 | 6         |
| 10 | Repeatability of $^{18}\text{F}$ -FDG PET Radiomic Features in Cervical Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 707-715.   | 2.8 | 12        |
| 11 | Quantitative Fit Tested N95 Respirator-Alternatives Generated With CT Imaging and 3D Printing: A Response to Potential Shortages During the COVID-19 Pandemic. <i>Academic Radiology</i> , 2021, 28, 158-165.   | 1.3 | 19        |
| 12 | Theranostics: The Role of Quantitative Nuclear Medicine Imaging. <i>Seminars in Radiation Oncology</i> , 2021, 31, 28-36.   | 1.0 | 10        |
| 13 | A Multisite Study of a Breast Density Deep Learning Model for Full-Field Digital Mammography and Synthetic Mammography. <i>Radiology: Artificial Intelligence</i> , 2021, 3, e200015.   | 3.0 | 23        |
| 14 | Quantitation of cancer treatment response by 2- $^{18}\text{F}$ FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST $^{\text{TM}}$ . <i>EJNMMI Research</i> , 2021, 11, 15.   | 1.1 | 4         |
| 15 | Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of $^{68}\text{Ga}$ DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy. <i>Molecular Imaging and Biology</i> , 2021, 23, 766-774. | 1.3 | 6         |
| 16 | Improved $^{223}\text{Ra}$ Therapy with Combination Epithelial Sodium Channel Blockade. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1751-1758.   | 2.8 | 10        |
| 17 | At Last, $^{18}\text{F}$ -FDG for Inflammation and Infection!. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1048-1049.  | 2.8 | 19        |
| 18 | Bioluminescent Tumor Signal Is Mouse Strain and Pelt Color Dependent: Experience in a Disseminated Lymphoma Model. <i>Molecular Imaging and Biology</i> , 2021, 23, 697-702.  | 1.3 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. <i>Cancers</i> , 2021, 13, 2828.              | 1.7 | 8         |
| 20 | Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century. <i>Journal of Nuclear Medicine</i> , 2021, 62, 34S-43S.  | 2.8 | 5         |
| 21 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.  | 0.8 | 22        |
| 22 | Detection of additional primary neoplasms on 18F-Fluciclovine PET/CT in patients with primary prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262647.  | 2.8 | 3         |
| 23 | PET Diagnosis and Response Monitoring in Oncology. , 2021, , 1049-1076.   |     | 0         |
| 24 | Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 6-14.   | 2.8 | 13        |
| 25 | Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 23S-35S.  | 2.8 | 32        |
| 26 | Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1S-2S.  | 2.8 | 4         |
| 27 | Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 60S-72S.  | 2.8 | 19        |
| 28 | Human Radiation Dosimetry for Orally and Intravenously Administered <sup>18</sup> F-FDG. <i>Journal of Nuclear Medicine</i> , 2020, 61, 613-619.  | 2.8 | 11        |
| 29 | The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. <i>Radiology</i> , 2020, 294, 647-657.  | 3.6 | 49        |
| 30 | Preclinical PERCIST and 25% of SUV <sub>max</sub> Threshold: Precision Imaging of Response to Therapy in Co-clinical <sup>18</sup> F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. <i>Journal of Nuclear Medicine</i> , 2020, 61, 842-849. | 2.8 | 12        |
| 31 | The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 471-483.  | 2.5 | 2         |
| 32 | Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. <i>Tomography</i> , 2020, 6, 60-64.   | 0.8 | 2         |
| 33 | Diagnosis of Stage IV Melanoma. , 2020, , 997-1043.   |     | 0         |
| 34 | Imaging Melanoma. , 2019, , 557-581.  |     | 0         |
| 35 | <sup>18</sup> F-FDG PET/CT Radiomic Analysis with Machine Learning for Identifying Bone Marrow Involvement in the Patients with Suspected Relapsed Acute Leukemia. <i>Theranostics</i> , 2019, 9, 4730-4739.  | 4.6 | 41        |
| 36 | Reply to E. Hindi et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2092-2093.   | 0.8 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with <sup>18</sup> F-Fluorodeoxyglucose in Humans. <i>Cell Metabolism</i> , 2019, 30, 212-224.e4.                   | 7.2 | 21        |
| 38 | Repeatability of brown adipose tissue measurements on FDG PET/CT following a simple cooling procedure for BAT activation. <i>PLoS ONE</i> , 2019, 14, e0214765.  | 1.1 | 19        |
| 39 | TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.              | 0.8 | 36        |
| 40 | Measurement Repeatability of <sup>18</sup> F-FDG PET/CT Versus <sup>18</sup> F-FDG PET/MRI in Solid Tumors of the Pelvis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1080-1086.                                    | 2.8 | 23        |
| 41 | Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks. <i>Journal of Nuclear Medicine</i> , 2019, 60, 437-438.   | 2.8 | 2         |
| 42 | Dynamic whole-body PET imaging: principles, potentials and applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 501-518.  | 3.3 | 145       |
| 43 | Diagnosis of Stage IV Melanoma. , 2019, , 1-47.  |     | 1         |
| 44 | Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , 2018, 25, 1405-1414.           | 1.3 | 29        |
| 45 | Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry and <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1243-1248.  | 2.8 | 22        |
| 46 | Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 320-332.  | 2.3 | 24        |
| 47 | Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with <sup>89</sup> Zr in Human Lymphoma Xenografts. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1219-1224.   | 2.8 | 28        |
| 48 | PERCIST in Perspective. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 1-4.   | 0.6 | 27        |
| 49 | Quantitative PET/CT in clinical practice. <i>Nuclear Medicine Communications</i> , 2018, 39, 154-160.  | 0.5 | 14        |
| 50 | Noninvasive methods for the assessment of brown adipose tissue in humans. <i>Journal of Physiology</i> , 2018, 596, 363-378.   | 1.3 | 43        |
| 51 | DNA Repair After Exposure to Ionizing Radiation Is Not Error-Free. <i>Journal of Nuclear Medicine</i> , 2018, 59, 348-348.   | 2.8 | 6         |
| 52 | Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1780-1781. | 2.8 | 2         |
| 53 | Spatial relationship of 2-deoxy-2-[ <sup>18</sup> F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. <i>EJNMMI Research</i> , 2018, 8, 52.          | 1.1 | 11        |
| 54 | The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1219-1235.                    | 0.4 | 30        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1014-1016.       | 2.8 | 19        |
| 56 | Imaging Melanoma. , 2018, , 1-25.   |     | 0         |
| 57 | Simplifying volumes of interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole organ VOIs. <i>Medical Physics</i> , 2017, 44, 1707-1717.   | 1.6 | 14        |
| 58 | Quantitation of Cancer Treatment Response by <sup>18</sup> F-FDG PET/CT: Multicenter Assessment of Measurement Variability. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1429-1434.                                 | 2.8 | 11        |
| 59 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 845-852.                        | 0.6 | 39        |
| 60 | The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. <i>Journal of Neuro-Oncology</i> , 2017, 132, 513-519.  | 1.4 | 38        |
| 61 | Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point <sup>18</sup> F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428. | 2.8 | 209       |
| 62 | Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. <i>Annals of Nuclear Medicine</i> , 2017, 31, 109-124.   | 1.2 | 24        |
| 63 | A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-III A resectable NSCLC. <i>EJNMMI Research</i> , 2017, 7, 8.  | 1.1 | 16        |
| 64 | Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. <i>Molecular Imaging and Biology</i> , 2017, 19, 429-436.                                    | 1.3 | 12        |
| 65 | Repeatability of <sup>18</sup> F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 393-398.   | 2.8 | 27        |
| 66 | Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2017, , 353-393.  |     | 0         |
| 67 | Radionuclide Therapy of Lymphomas. , 2017, , 1141-1155.   |     | 0         |
| 68 | Quo Vadis: PET and Single-Photon Molecular Breast Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 3S-8S.  | 2.8 | 6         |
| 69 | Comparison of quantitative <sup>90</sup> Y SPECT and non- <sup>90</sup> Y PET imaging in post-therapy radioembolization of liver cancer. <i>Medical Physics</i> , 2016, 43, 5779-5790.                                | 1.6 | 32        |
| 70 | Brown Adipose Reporting Criteria in Imaging Studies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans. <i>Cell Metabolism</i> , 2016, 24, 210-222.                                     | 7.2 | 233       |
| 71 | Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 3680-3685.   | 0.8 | 17        |
| 72 | Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma. <i>EJNMMI Research</i> , 2016, 6, 42.   | 1.1 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 1304-1314.  | 1.4 | 18        |
| 74 | Quantitative Imaging in Cancer Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 284-290.   | 3.2 | 106       |
| 75 | Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 293-300.   | 0.5 | 16        |
| 76 | Response to Early Treatment Evaluated with <sup>18</sup> F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor. <i>Journal of Nuclear Medicine</i> , 2016, 57, 735-740. | 2.8 | 25        |
| 77 | Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. <i>Radiology</i> , 2016, 280, 576-584.   | 3.6 | 311       |
| 78 | Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2016, , 1-42.  |     | 0         |
| 79 | Radionuclide Therapy of Lymphomas. , 2016, , 1-15.   |     | 0         |
| 80 | Optimal definition of biological tumor volume using positron emission tomography in an animal model. <i>EJNMMI Research</i> , 2015, 5, 58.   | 1.1 | 7         |
| 81 | Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET. <i>Physics in Medicine and Biology</i> , 2015, 60, 8643-8673.  | 1.6 | 78        |
| 82 | Case Report. <i>Medicine (United States)</i> , 2015, 94, e1820.  | 0.4 | 0         |
| 83 | Observational Retrospective Study of Altered Biodistribution of Tositumomab and <sup>131</sup> I-Tositumomab. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1800-1803.  | 2.8 | 1         |
| 84 | Two-Time-Point FDG PET/CT: Liver SUL <sub>mean</sub> Repeatability. <i>American Journal of Roentgenology</i> , 2015, 204, 402-407.   | 1.0 | 10        |
| 85 | Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. <i>American Journal of Roentgenology</i> , 2015, 204, 1093-1099.   | 1.0 | 52        |
| 86 | Summary of the UPICT Protocol for <sup>18</sup> F-FDG PET/CT Imaging in Oncology Clinical Trials. <i>Journal of Nuclear Medicine</i> , 2015, 56, 955-961.  | 2.8 | 93        |
| 87 | <sup>18</sup> F-FDG PET/CT and Lung Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. <i>Journal of Nuclear Medicine</i> , 2015, 56, 204-208.   | 2.8 | 29        |
| 88 | Longitudinal Myocardial Blood Flow Gradient and CAD Detection. <i>Current Cardiology Reports</i> , 2015, 17, 550.  | 1.3 | 3         |
| 89 | Performance assessment of a NaI(Tl) gamma counter for PET applications with methods for improved quantitative accuracy and greater standardization. <i>EJNMMI Physics</i> , 2015, 2, .   | 1.3 | 18        |
| 90 | Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. <i>Statistical Methods in Medical Research</i> , 2015, 24, 27-67.   | 0.7 | 272       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Comprehensive Radionuclide Esophagogastrointestinal Transit Study: Methodology, Reference Values, and Initial Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2015, 56, 721-727.   | 2.8 | 31        |
| 92  | Liver Standardized Uptake Value Corrected for Lean Body Mass at FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e17-e22.  | 0.7 | 22        |
| 93  | Repeatability of Radiotracer Uptake in Normal Abdominal Organs with <sup>111</sup> In-Pentetreotide Quantitative SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 985-988.   | 2.8 | 7         |
| 94  | Hyaluronic acid-serum hydrogels rapidly restore metabolism of encapsulated stem cells and promote engraftment. <i>Biomaterials</i> , 2015, 73, 1-11.   | 5.7 | 30        |
| 95  | Metrology Standards for Quantitative Imaging Biomarkers. <i>Radiology</i> , 2015, 277, 813-825.  | 3.6 | 347       |
| 96  | Strengths and Weaknesses of a Planar Whole-Body Method of <sup>153</sup> Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 369-379.                                      | 0.7 | 9         |
| 97  | TBCRC 008: Early Change in <sup>18</sup> F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.                                   | 2.8 | 61        |
| 98  | <sup>18</sup> F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2337-2345.  | 3.3 | 10        |
| 99  | Letter to Cancer Center Directors: Progress in Quantitative Imaging As a Means to Predict and/or Measure Tumor Response in Cancer Therapy Trials. <i>Journal of Clinical Oncology</i> , 2014, 32, 2115-2116.   | 0.8 | 16        |
| 100 | Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data. <i>EJNMMI Research</i> , 2014, 4, 67.  | 1.1 | 19        |
| 101 | Respiratory-gated PET/CT versus delayed images for the quantitative evaluation of lower pulmonary and hepatic lesions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 277-282.   | 0.9 | 16        |
| 102 | Prognostic Value of FDG PET Metabolic Tumor Volume in Human Papillomavirus-Positive Stage III and IV Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Roentgenology</i> , 2014, 203, 897-903.   | 1.0 | 44        |
| 103 | Quantitative FDG PET/CT in the community: Experience from interpretation of outside oncologic PET/CT exams in referred cancer patients. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 183-188.  | 0.9 | 11        |
| 104 | FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2014, 39, 225-231.   | 0.7 | 79        |
| 105 | Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies ( <sup>131</sup> I-Tositumomab and Tositumomab, $\text{\textcircled{B}}$ Bexxar $\text{\textcircled{B}}$ ). <i>Medical Radiology</i> , 2014, , 505-525.  | 0.0 | 0         |
| 106 | Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 539-546. | 0.4 | 70        |
| 107 | Absolute myocardial flow quantification with <sup>82</sup> Rb PET/CT: comparison of different software packages and methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 126-135.  | 3.3 | 77        |
| 108 | An Exocrine Pancreatic Stress Test with <sup>11</sup> C-Acetate PET and Secretin Stimulation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1128-1131.  | 2.8 | 6         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Follow-up or Surveillance <sup>18</sup> F-FDG PET/CT and Survival Outcome in Lung Cancer Patients. Journal of Nuclear Medicine, 2014, 55, 1062-1068.   | 2.8 | 45        |
| 110 | Quantitative Assessment of Myocardial Blood Flow—Clinical and Research Applications. Seminars in Nuclear Medicine, 2014, 44, 274-293.  | 2.5 | 52        |
| 111 | Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging. Journal of Nuclear Medicine, 2014, 55, 1481-1484.  | 2.8 | 83        |
| 112 | Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 596-604.                           | 3.3 | 38        |
| 113 | Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria)—Interreader Reliability, Accuracy, and Survival Outcomes. Journal of Nuclear Medicine, 2014, 55, 1411-1416.  | 2.8 | 156       |
| 114 | Imaging Metabolic and Molecular Functions in Brain Tumors with Positron Emission Tomography (PET)., 2014, , 129-142.   |     | 0         |
| 115 | Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.. Journal of Clinical Oncology, 2014, 32, 189-189. | 0.8 | 1         |
| 116 | Functional Imaging. Medical Radiology, 2014, , 159-166.  | 0.0 | 0         |
| 117 | The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma. Journal of Radiation Oncology, 2013, 2, 341-352.   | 0.7 | 7         |
| 118 | Cardiac PET/CT Misregistration Causes Significant Changes in Estimated Myocardial Blood Flow. Journal of Nuclear Medicine, 2013, 54, 50-54.  | 2.8 | 43        |
| 119 | Addition of <sup>18</sup> F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years. Journal of Nuclear Medicine, 2013, 54, 2039-2045.                            | 2.8 | 39        |
| 120 | Study of the Impact of Tissue Density Heterogeneities on 3-Dimensional Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo Methods. Journal of Nuclear Medicine, 2013, 54, 236-243.               | 2.8 | 57        |
| 121 | Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma. Journal of Nuclear Medicine, 2013, 54, 1535-1542.  | 2.8 | 20        |
| 122 | Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation. Physics in Medicine and Biology, 2013, 58, 7419-7445.   | 1.6 | 84        |
| 123 | Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. Physics in Medicine and Biology, 2013, 58, 7391-7418.   | 1.6 | 172       |
| 124 | Relationship of Delayed Enhancement by Magnetic Resonance to Myocardial Perfusion by Positron Emission Tomography in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2013, 6, 210-217.                             | 1.3 | 54        |
| 125 | Quantitative whole-body parametric PET imaging incorporating a generalized Patlak model. , 2013, , .   |     | 5         |
| 126 | Surveillance of Cancer Patients with Imaging: Self-Evident or Evidence-Based?. Journal of Nuclear Medicine, 2013, 54, 1513-1515.   | 2.8 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).. Journal of Clinical Oncology, 2013, 31, TPS2105-TPS2105.  | 0.8 | 2         |
| 128 | Lymphomas. , 2013, , 153-187.  |     | 0         |
| 129 | Enhanced whole-body PET parametric imaging using hybrid regression and thresholding driven by kinetic correlations. , 2012, , .  |     | 4         |
| 130 | PET/CT Assessment of Symptomatic Individuals with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy. Journal of Nuclear Medicine, 2012, 53, 407-414.  | 2.8 | 46        |
| 131 | Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value. Journal of Nuclear Medicine, 2012, 53, 1041-1047.  | 2.8 | 186       |
| 132 | PET/CT findings in gastric cancer: potential advantages and current limitations. Imaging in Medicine, 2012, 4, 241-250.  | 0.0 | 9         |
| 133 | Hyaluronic acid-human blood hydrogels for stem cell transplantation. Biomaterials, 2012, 33, 8026-8033.  | 5.7 | 56        |
| 134 | Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. Translational Research, 2012, 159, 51-57.   | 2.2 | 34        |
| 135 | Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. British Journal of Clinical Pharmacology, 2012, 74, 1013-1022.   | 1.1 | 20        |
| 136 | Comparison and Effectiveness of Regadenoson Versus Dipyridamole on Stress Electrocardiographic Changes During Positron Emission Tomography Evaluation of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 1033-1039.  | 0.7 | 22        |
| 137 | Promise and pitfalls of quantitative imaging in oncology clinical trials. Magnetic Resonance Imaging, 2012, 30, 1301-1312.   | 1.0 | 83        |
| 138 | Tumor Dosimetry and Response for <sup>153</sup> Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma. Journal of Nuclear Medicine, 2012, 53, 215-224.   | 2.8 | 36        |
| 139 | Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. Journal of Clinical Oncology, 2012, 30, 10509-10509. | 0.8 | 3         |
| 140 | Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/paraganglioma (Pheo).. Journal of Clinical Oncology, 2012, 30, e13592-e13592.   | 0.8 | 3         |
| 141 | Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma. Nuclear Medicine Communications, 2011, 32, 1046-1051.  | 0.5 | 19        |
| 142 | The Promise and Pitfalls of Positron Emission Tomography and Single-Photon Emission Computed Tomography Molecular Imaging—Guided Radiation Therapy. Seminars in Radiation Oncology, 2011, 21, 88-100.  | 1.0 | 57        |
| 143 | The Relationship between Patients'™ Serum Glucose Levels and Metabolically Active Brown Adipose Tissue Detected by PET/CT. Molecular Imaging and Biology, 2011, 13, 1278-1283.   | 1.3 | 56        |
| 144 | Three-dimensional radiobiological dosimetry (3D-RD) with <sup>124</sup> I PET for <sup>131</sup> I therapy of thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 41-47.   | 3.3 | 52        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Myocardial substrate and route of administration determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 443-450.  | 1.4 | 69        |
| 146 | A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1256-1262.   | 0.4 | 49        |
| 147 | Synthesis and in vivo evaluation of (S)-6-(4-fluorophenoxy)-3-((1-[ <sup>11</sup> C]methylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one, a potential PET tracer for growth hormone secretagogue receptor (GHSR). <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2368-2372. | 1.4 | 17        |
| 148 | Dynamic Multi-Bed FDG PET imaging: Feasibility and optimization. , 2011, , .   |     | 28        |
| 149 | Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists. <i>Journal of Nuclear Medicine</i> , 2011, 52, 830-838.   | 2.8 | 40        |
| 150 | Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey. <i>Journal of Nuclear Medicine</i> , 2011, 52, 311-317.   | 2.8 | 96        |
| 151 | Effect of Patient Arm Motion in Whole-Body PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1891-1897.   | 2.8 | 23        |
| 152 | Assessment of Tumoricidal Efficacy and Response to Treatment with <sup>18</sup> F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. <i>Journal of Nuclear Medicine</i> , 2011, 52, 225-230.                         | 2.8 | 17        |
| 153 | Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of U.S. Medical Oncologists and Hematologists. <i>Journal of Nuclear Medicine</i> , 2010, 51, 987-994.  | 2.8 | 36        |
| 154 | Characterization of a Perirectal Artifact in <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1501-1506.   | 2.8 | 11        |
| 155 | CT Hounsfield Units of Brown Adipose Tissue Increase with Activation: Preclinical and Clinical Studies. <i>Journal of Nuclear Medicine</i> , 2010, 51, 246-250.  | 2.8 | 161       |
| 156 | Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with <sup>90</sup> Y-ibritumomab Tiuxetan or <sup>131</sup> I-Tositumomab. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1878-1884.   | 2.8 | 27        |
| 157 | Overcorrection of iodinated contrast attenuation in SPECT-CT: Phantom studies. <i>Medical Physics</i> , 2010, 37, 4897-4901.   | 1.6 | 7         |
| 158 | Simultaneous measurement of noise and spatial resolution in PET phantom images. <i>Physics in Medicine and Biology</i> , 2010, 55, 1069-1081.  | 1.6 | 28        |
| 159 | The Roles of Fluorodeoxyglucose-PET/Computed Tomography in Ovarian Cancer: Diagnosis, Assessing Response, and Detecting Recurrence. <i>PET Clinics</i> , 2010, 5, 447-461.   | 1.5 | 2         |
| 160 | Arterial Wall Dosimetry for Non-Hodgkin Lymphoma Patients Treated with Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2010, 51, 368-375.   | 2.8 | 12        |
| 161 | Measuring the "Unmeasurable". <i>Academic Radiology</i> , 2010, 17, 1175-1185.   | 1.3 | 5         |
| 162 | <sup>18</sup> F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 8-17.   | 2.8 | 66        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | A Practical, Automated Quality Assurance Method for Measuring Spatial Resolution in PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1307-1314.  | 2.8 | 26        |
| 164 | Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning in patient studies. <i>Medical Physics</i> , 2009, 36, 1595-1601.   | 1.6 | 26        |
| 165 | Prediction of the Need for Surgical Intervention in Obstructive Crohn's Disease by <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1751-1759.  | 2.8 | 67        |
| 166 | Assessment of Interobserver Reproducibility in Quantitative <sup>18</sup> F-FDG PET and CT Measurements of Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1760-1769.   | 2.8 | 65        |
| 167 | <sup>124</sup> I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1844-1847.  | 2.8 | 80        |
| 168 | The Added Diagnostic Value of Liquid Gastric Emptying Compared with Solid Emptying Alone. <i>Journal of Nuclear Medicine</i> , 2009, 50, 726-731.   | 2.8 | 81        |
| 169 | Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. <i>Investigational New Drugs</i> , 2009, 27, 120-123.   | 1.2 | 33        |
| 170 | Imaging Uterine Cervical Cancer with FDG-PET/CT: Direct Comparison with PET. <i>Molecular Imaging and Biology</i> , 2009, 11, 229-235.  | 1.3 | 19        |
| 171 | Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 242-248.  | 2.0 | 64        |
| 172 | Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. <i>Medical Physics</i> , 2009, 36, 612-619.                         | 1.6 | 46        |
| 173 | Clinical Significance of Iodine-123 Metaiodobenzylguanidine Cardiac Imaging. <i>Journal of the American College of Cardiology</i> , 2009, 54, 575-576.  | 1.2 | 0         |
| 174 | Noninvasive Quantification and Optimization of Acute Cell Retention by In Vivo Positron Emission Tomography After Intramyocardial Cardiac-Derived Stem Cell Delivery. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1619-1626. | 1.2 | 245       |
| 175 | From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 122S-150S.  | 2.8 | 3,047     |
| 176 | Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic Decisions. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 308-340.   | 2.5 | 118       |
| 177 | <sup>18</sup> F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1655-1665.   | 2.8 | 129       |
| 178 | Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results. <i>Blood</i> , 2009, 114, 3759-3759.  | 0.6 | 12        |
| 179 | Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications. <i>PLoS ONE</i> , 2009, 4, e6200.  | 1.1 | 17        |
| 180 | Scalene muscle uptake: a potential pitfall in head and neck PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 89-94.  | 3.3 | 20        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Comparison of FDG-PET/CT and CT for Delineation of Lumpectomy Cavity for Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2008, 71, 595-602.  | 0.4 | 25        |
| 182 | Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning—Monte Carlo Simulation Studies. IEEE Transactions on Medical Imaging, 2008, 27, 521-530.  | 5.4 | 48        |
| 183 | Ectopic Expression of the Sodium-Iodide Symporter Enables Imaging of Transplanted Cardiac Stem Cells In Vivo by Single-Photon Emission Computed Tomography or Positron Emission Tomography. Journal of the American College of Cardiology, 2008, 52, 1652-1660. | 1.2 | 166       |
| 184 | Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Medical Physics, 2008, 35, 1123-1134.  | 1.6 | 70        |
| 185 | In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab. Journal of Nuclear Medicine, 2008, 49, 674-678.   | 2.8 | 25        |
| 186 | Reproducibility of Tumor Blood Flow Quantification with <sup>15</sup> O-Water PET. Journal of Nuclear Medicine, 2008, 49, 1620-1627.  | 2.8 | 35        |
| 187 | Diagnosis and Differentiation of Bronchioloalveolar Carcinoma from Adenocarcinoma with Bronchioloalveolar Components with Metabolic and Anatomic Characteristics Using PET/CT. Journal of Nuclear Medicine, 2008, 49, 1585-1592.                                | 2.8 | 45        |
| 188 | Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 32-37.  | 1.3 | 32        |
| 189 | Visualization of Brown Adipose Tissue with <sup>99m</sup> Tc-Methoxyisobutylisonitrile on SPECT/CT. Journal of Nuclear Medicine, 2008, 49, 752-756.   | 2.8 | 42        |
| 190 | FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Current Opinion in Oncology, 2008, 20, 206-219.   | 1.1 | 60        |
| 191 | Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety. Blood, 2008, 112, 3059-3059.                                       | 0.6 | 7         |
| 192 | Advantages of Hybrid SPECT/CT vs SPECT Alone. The Open Medical Imaging Journal, 2008, 2, 67-79.   | 0.8 | 22        |
| 193 | Individualizing cancer therapies using "anatomolecular" imaging. Journal of Nuclear Medicine, 2008, 49, 65N-68N.  | 2.8 | 0         |
| 194 | Effect of Nicotine and Ephedrine on the Accumulation of 18F-FDG in Brown Adipose Tissue. Journal of Nuclear Medicine, 2007, 48, 981-986.  | 2.8 | 61        |
| 195 | Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry. Journal of Nuclear Medicine, 2007, 48, 1008-1016.  | 2.8 | 123       |
| 196 | Comparison of Uptake of Multiple Clinical Radiotracers into Brown Adipose Tissue Under Cold-Stimulated and Nonstimulated Conditions. Journal of Nuclear Medicine, 2007, 48, 1715-1723.  | 2.8 | 52        |
| 197 | Hyperosmolar Sexual Lubricant Causes Epithelial Damage in the Distal Colon: Potential Implication for HIV Transmission. Journal of Infectious Diseases, 2007, 195, 703-710.   | 1.9 | 135       |
| 198 | <sup>18</sup> F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies. Journal of Nuclear Medicine, 2007, 48, 1923-1931.  | 2.8 | 39        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1767-1776.   | 2.8 | 81        |
| 200 | Extramedullary Hematopoiesis on F-18 FDG PET/CT in a Patient With Metastatic Colon Carcinoma. <i>Clinical Nuclear Medicine</i> , 2007, 32, 878-880.   | 0.7 | 11        |
| 201 | FDG-PET Lymphoma Demonstration Project Invitational Workshop. <i>Academic Radiology</i> , 2007, 14, 330-339.  | 1.3 | 27        |
| 202 | How Reproducible Is Bioluminescent Imaging of Tumor Cell Growth? Single Time Point versus the Dynamic Measurement Approach. <i>Molecular Imaging</i> , 2007, 6, 7290.2007.00031.  | 0.7 | 22        |
| 203 | Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 200-206.  | 1.4 | 81        |
| 204 | Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 961-969. | 0.9 | 77        |
| 205 | Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy. <i>Blood</i> , 2007, 110, 1894-1894.  | 0.6 | 2         |
| 206 | Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. <i>Journal of Nuclear Medicine</i> , 2007, 48, 150-7.        | 2.8 | 27        |
| 207 | Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. <i>Journal of Nuclear Medicine</i> , 2007, 48 Suppl 1, 19S-27S.   | 2.8 | 22        |
| 208 | How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. <i>Molecular Imaging</i> , 2007, 6, 315-22.   | 0.7 | 18        |
| 209 | Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 379-381.   | 0.7 | 27        |
| 210 | Initial experience with FDG-PET/CT in the evaluation of breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 254-262.   | 3.3 | 133       |
| 211 | Synthesis of 2-[18F]fluoroadenosine (2-[18F]FAD) as potential radiotracer for studying malignancies by PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 811-815.  | 0.5 | 7         |
| 212 | Preoperative Positron Emission Tomography to Evaluate Potentially Resectable Hepatic Colorectal Metastases. <i>Archives of Surgery</i> , 2006, 141, 1220.   | 2.3 | 50        |
| 213 | PET and PET/CT Imaging in Breast Cancer. , 2006, , 197-215.   |     | 0         |
| 214 | Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1985-94.   | 2.8 | 53        |
| 215 | Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1977-84.  | 2.8 | 34        |
| 216 | Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. <i>Journal of Nuclear Medicine</i> , 2006, 47, 603-8.  | 2.8 | 44        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 217 | Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. Journal of Nuclear Medicine, 2006, 47, 950-6.  | 2.8  | 43        |
| 218 | Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT. Journal of Nuclear Medicine, 2006, 47, 1274-80.  | 2.8  | 53        |
| 219 | Business Models for Academic Medical Center Cyclotron Operations. Journal of the American College of Radiology, 2005, 2, 526-533.   | 0.9  | 0         |
| 220 | Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecologic Oncology, 2005, 98, 510-512.  | 0.6  | 7         |
| 221 | Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecologic Oncology, 2005, 99, 294-300.   | 0.6  | 100       |
| 222 | Synthesis and Biodistribution of [11C]Adenosine 5'-Monophosphate ([11C]AMP). Molecular Imaging and Biology, 2005, 7, 203-208.   | 1.3  | 15        |
| 223 | Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab. Journal of Clinical Oncology, 2005, 23, 7985-7993.   | 0.8  | 93        |
| 224 | Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2005, 23, 7565-7573. | 0.8  | 226       |
| 225 | CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT Examination. Radiology, 2005, 237, 627-634.   | 3.6  | 107       |
| 226 | Direct Comparison of FDG PET and CT Findings in Patients with Lymphoma: Initial Experience. Radiology, 2005, 237, 1038-1045.  | 3.6  | 130       |
| 227 | Dynamic Imaging of Allogeneic Mesenchymal Stem Cells Trafficking to Myocardial Infarction. Circulation, 2005, 112, 1451-1461.   | 1.6  | 561       |
| 228 | Normal FDG Distribution Patterns in the Head and Neck: PET/CT Evaluation. Radiology, 2005, 234, 879-885.  | 3.6  | 254       |
| 229 | Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET. Radiographics, 2005, 25, 1031-1043.   | 1.4  | 143       |
| 230 | Tumor Response Assessment Is More Robust With Sequential CT Scanning Than External Caliper Measurements. Academic Radiology, 2005, 12, 776-781.   | 1.3  | 23        |
| 231 | 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. New England Journal of Medicine, 2005, 352, 441-449.   | 13.9 | 697       |
| 232 | Applications of PET in Liver Imaging. Radiologic Clinics of North America, 2005, 43, 849-860.   | 0.9  | 27        |
| 233 | Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 128S-40S.  | 2.8  | 21        |
| 234 | Detection of unexpected additional primary malignancies with PET/CT. Journal of Nuclear Medicine, 2005, 46, 752-7.  | 2.8  | 174       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 277-285.                 | 0.8 | 314       |
| 236 | The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7792-7798.   | 3.2 | 142       |
| 237 | Bacteriolytic therapy can generate a potent immune response against experimental tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15172-15177.                                      | 3.3 | 244       |
| 238 | PET-CT in Recurrent Ovarian Cancer: Initial Observations. <i>Radiographics</i> , 2004, 24, 209-223.  | 1.4 | 79        |
| 239 | Clinical use of positron emission tomography in the management of cutaneous melanoma. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 242-253.   | 2.5 | 86        |
| 240 | PET/CT: artifacts caused by bowel motion. <i>Nuclear Medicine Communications</i> , 2004, 25, 221-225.  | 0.5 | 52        |
| 241 | F-18 FDG PET/CT in Acute Respiratory Distress Syndrome: A Case Report. <i>Clinical Nuclear Medicine</i> , 2004, 29, 786-788.   | 0.7 | 16        |
| 242 | FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. <i>Current Opinion in Oncology</i> , 2004, 16, 100-105.  | 1.1 | 20        |
| 243 | Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. <i>Journal of Nuclear Medicine</i> , 2004, 45 Suppl 1, 82S-95S.  | 2.8 | 28        |
| 244 | Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1189-93.  | 2.8 | 112       |
| 245 | Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 40-45.   | 3.3 | 33        |
| 246 | FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 274-280.   | 3.3 | 85        |
| 247 | Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 603-606.   | 3.3 | 216       |
| 248 | PET-CT: accuracy of PET and CT spatial registration of lung lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 721-726.  | 3.3 | 132       |
| 249 | Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 597-602.   | 3.3 | 72        |
| 250 | Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. <i>Gynecologic Oncology</i> , 2003, 90, 519-528.  | 0.6 | 189       |
| 251 | Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements. <i>Seminars in Nuclear Medicine</i> , 2003, 33, 228-237. | 2.5 | 149       |
| 252 | A Positron-Emitting Internal Marker for Identification of Normal Tissue by Positron Emission Tomography: Phantom Studies and Validation in Patients. <i>Molecular Imaging and Biology</i> , 2003, 5, 79-85.                                    | 1.3 | 4         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Anatomolecular Imaging with 2-Deoxy-2-[18F]Fluoro-D-Glucose: Bench to Outpatient Center. <i>Molecular Imaging and Biology</i> , 2003, 5, 49-56.  | 1.3 | 12        |
| 254 | Effects of Nonionic Intravenous Contrast Agents at PET/CT Imaging: Phantom and Canine Studies. <i>Radiology</i> , 2003, 227, 817-824.  | 3.6 | 106       |
| 255 | Fluorodeoxyglucose Uptake in the Aortic Wall at PET/CT: Possible Finding for Active Atherosclerosis. <i>Radiology</i> , 2003, 229, 831-837.  | 3.6 | 207       |
| 256 | Indium-111 <sup>Î</sup> Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1715-1721. | 0.8 | 108       |
| 257 | <b>Sacral Fractures:</b> A Potential Pitfall of FDG Positron Emission Tomography. <i>American Journal of Roentgenology</i> , 2003, 181, 1239-1243.   | 1.0 | 46        |
| 258 | The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. <i>Seminars in Oncology</i> , 2003, 30, 31-38.   | 0.8 | 65        |
| 259 | Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2003, 44, 170-6.   | 2.8 | 289       |
| 260 | Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 240-3.  | 2.8 | 160       |
| 261 | Initial experience with oral contrast in PET/CT: phantom and clinical studies. <i>Journal of Nuclear Medicine</i> , 2003, 44, 412-6.   | 2.8 | 85        |
| 262 | Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 457-64.   | 2.8 | 48        |
| 263 | "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1267-70.  | 2.8 | 189       |
| 264 | Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1541-3; author reply 1543.   | 2.8 | 19        |
| 265 | Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. <i>Cancer Research</i> , 2003, 63, 6252-7.                                 | 0.4 | 50        |
| 266 | Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1797-803.  | 2.8 | 215       |
| 267 | PET Scanning and Measuring the Impact of Treatment. <i>Cancer Journal (Sudbury, Mass )</i> , 2002, 8, 119-134.   | 1.0 | 19        |
| 268 | Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography using 2-Deoxy-2-[18F]Fluoro-D-Glucose. <i>Molecular Imaging and Biology</i> , 2002, 4, 171-178.       | 1.3 | 93        |
| 269 | Expression of hexokinase II and Glut-1 in untreated human breast cancer. <i>Nuclear Medicine and Biology</i> , 2002, 29, 443-453.  | 0.3 | 129       |
| 270 | Radiosynthesis of [11C]paclitaxel. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 471-477.  | 0.5 | 17        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. <i>Cancer</i> , 2002, 94, 1258-1263.   | 2.0 | 31        |
| 272 | Prognostic Value of Positron Emission Tomography Using F-18-Fluorodeoxyglucose in Patients with Cervical Cancer Undergoing Radiotherapy. <i>Gynecologic Oncology</i> , 2002, 84, 289-295.   | 0.6 | 61        |
| 273 | PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1137-43.  | 2.8 | 97        |
| 274 | Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2001, 19, 3918-3928.   | 0.8 | 555       |
| 275 | Current status of PET in breast cancer imaging, staging, and therapy. <i>Seminars in Roentgenology</i> , 2001, 36, 250-260.   | 0.2 | 78        |
| 276 | Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. <i>Blood</i> , 2000, 96, 1259-1266.   | 0.6 | 465       |
| 277 | Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 1316-1323.  | 0.8 | 337       |
| 278 | Metastases from Non-Small Cell Lung Cancer: Mediastinal Staging in the 1990s—Meta-analytic Comparison Of PET and CT. <i>Radiology</i> , 1999, 213, 530-536.   | 3.6 | 613       |
| 279 | Head and Neck Cancer: Detection of Recurrence with Three-dimensional Principal Components Analysis at Dynamic FDG PET. <i>Radiology</i> , 1999, 212, 285-290.   | 3.6 | 42        |
| 280 | Germ Cell Tumor: Differentiation of Viable Tumor, Mature Teratoma, and Necrotic Tissue with FDG PET and Kinetic Modeling. <i>Radiology</i> , 1999, 211, 249-256.  | 3.6 | 112       |
| 281 | Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants. <i>Radiographics</i> , 1999, 19, 61-77.  | 1.4 | 757       |
| 282 | Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction. <i>Radiology</i> , 1999, 213, 521-525.   | 3.6 | 222       |
| 283 | Bone marrow cell trafficking following intravenous administration. <i>British Journal of Haematology</i> , 1999, 107, 895-902.  | 1.2 | 78        |
| 284 | Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 39-45.  | 3.3 | 59        |
| 285 | Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67 Ga-citrate, and 125 I-HSA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 333-341.   | 3.3 | 103       |
| 286 | Semi-quantitative ventilation/perfusion scintigraphy and single-photon emission tomography for evaluation of lung volume reduction surgery candidates: description and prediction of clinical outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 734-742. | 3.3 | 44        |
| 287 | Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1238-1243.   | 3.3 | 210       |
| 288 | FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT. <i>Molecular Imaging and Biology</i> , 1998, 1, 123-129.   | 0.3 | 47        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 289 | Positron Emission Tomography (PET): an Update on Applications in Breast Cancer. <i>Breast Disease</i> , 1998, 10, 165-175.  | 0.4  | 3         |
| 290 | Preliminary assessment of fluorine-18 fluorodeoxyglucose positron mission tomography in patients with bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 615-620.          | 2.2  | 126       |
| 291 | Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 1997, 24, 657-663.  | 0.3  | 19        |
| 292 | Magnetically-enhanced radionuclide therapy (MERiT): In vitro evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 1201-1206.  | 0.4  | 9         |
| 293 | Regional 2-[18F]fluoro-2-deoxy-d-glucose uptake varies in normal lung. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 517-523.   | 2.2  | 43        |
| 294 | Exposure to strong static magnetic field slows the growth of human cancer cells in vitro. <i>Bioelectromagnetics</i> , 1996, 17, 358-363.   | 0.9  | 129       |
| 295 | Evaluation of ion-implanted-silicon detectors for use in intraoperative positron-sensitive probes. <i>Medical Physics</i> , 1996, 23, 1889-1895.  | 1.6  | 26        |
| 296 | Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: Theory of application. <i>Medical Physics</i> , 1995, 22, 1285-1292.                                       | 1.6  | 3         |
| 297 | Experimental radioimmunotherapy. A brief overview. <i>Cancer</i> , 1994, 73, 989-992.   | 2.0  | 11        |
| 298 | Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study. <i>Cancer</i> , 1993, 72, 2979-2985.  | 2.0  | 521       |
| 299 | Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody. <i>New England Journal of Medicine</i> , 1993, 329, 459-465.   | 13.9 | 531       |
| 300 | Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study. , 1993, 72, 2979.   |      | 3         |
| 301 | Uptake of 2-Deoxy, 2-(18F) Fluoro-D-Glucose in Bladder Cancer: Animal Localization and Initial Patient Positron Emission Tomography. <i>Journal of Urology</i> , 1991, 145, 279-283.                                  | 0.2  | 55        |
| 302 | Imaging of Renal Cancer Using Positron Emission Tomography with 2-Deoxy-2-(18F)-Fluoro-D-Glucose: Pilot Animal and Human Studies. <i>Journal of Urology</i> , 1991, 146, 1470-1474.                                   | 0.2  | 73        |
| 303 | 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. <i>Cancer</i> , 1991, 67, 1544-1550.                                     | 2.0  | 200       |
| 304 | Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1991, 18, 432-435. | 2.2  | 5         |
| 305 | Studies on the metabolic fate of 111In-labeled antibodies. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1989, 16, 839-845.                       | 0.3  | 7         |
| 306 | High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts. <i>Cancer Immunology, Immunotherapy</i> , 1987, 24, 221-4.                         | 2.0  | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 307 | Diagnosis of exercise-induced left bundle branch block at rest by scintigraphic phase analysis. European Journal of Nuclear Medicine and Molecular Imaging, 1986, 11, 434-7.                                | 2.2 | 2         |
| 308 | Increased genital uptake of 99mTc red blood cells: A potential cause of false-positive studies for gastrointestinal bleeding. European Journal of Nuclear Medicine and Molecular Imaging, 1984, 9, 245-246. | 2.2 | 2         |
| 309 | The effect of specimen processing on radiolabeled monoclonal antibody biodistribution. European Journal of Nuclear Medicine and Molecular Imaging, 1984, 9, 382-4.  | 2.2 | 14        |
| 310 | Use of combined PET/CT imaging in evaluation of the solitary pulmonary nodule: Principles, techniques, and pitfalls. , 0, , 24-43.  |     | 0         |